BioSpace News Archive

GBS Inc. announced its financial results for the third quarter ended March 31, 2022 and provided recent business updates.

Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat addictions and drug overdose, today reported financial results for the three months ended March 31, 2022, and provided a corporate update.

Singular Genomics Systems, Inc. announced the company is collaborating with NVIDIA to validate and optimize the performance of the G4 Sequencing Platform with NVIDIA Clara Parabricks for secondary analysis including alignment and variant calling with over 50 tools for germline and somatic workflows.

Cardinal Health announced that its Board of Directors approved a quarterly dividend of $0.4957 per share out of the Company’s capital surplus.

Catalyst Pharmaceuticals, Inc. (“Catalyst”) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare diseases, today reported financial results for the first quarter 2022 and provided a corporate update.

Exelixis, Inc. reported financial results for the first quarter of 2022 and provided an update on progress toward achieving key corporate objectives, as well as commercial, clinical and pipeline development milestones.

Revance Therapeutics, Inc., a biotechnology company focused on innovative aesthetic and therapeutic offerings, reported financial results for the first quarter ended March 31, 2022 and provided a corporate update.

OraSure Technologies, Inc. announced its financial results for the three months ended March 31, 2022.

Sana Biotechnology, Inc., a company focused on creating and delivering engineered cells as medicines, reported financial results and business highlights for the first quarter 2022.

Talis Biomedical Corporation reported financial results for the first quarter ended March 31, 2022.